rucaparib,abiraterone,docetaxel,enzalutamide
Clovis Oncology,Astellas,Pfizer
['gu ', 'rucaparib', 'brca', 'crpc', 'prostate']
presented at asco gu 2023! trial in pts with advanced prostate cancer . rucaparib vs physician choice of with doc or abi/enza improved pfs and suggest a trend towards improvement in os in pts with mcrpc and brca/atm mut
#ascogu23 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"